Sanofi to sell stake in Covid-19 treatment maker Regeneron
26th May 2020 11:59
(Sharecast News) - Sanofi will sell its stake in US-based maker of Covid-19 treatments Regeneron Pharmaceuticals.
Read moreOxford University's push for Covid-19 vaccine may stumble due to drop in infections
26th May 2020 11:53
(Sharecast News) - Oxford University's attempts to develop a vaccine against the novel coronavirus could run into an apparently unexpected hurdle, the head of its research team said.
Read moreNovavax begins trialling Covid-19 vaccine in Australia
26th May 2020 11:11
(Sharecast News) - Biotechnology firm Novavax has begun trialling a Covid-19 vaccine candidate in Australia as it hopes to release a proven vaccine by the end of 2020.
Read moreFauci predicts US could have vaccine by end of 2020
22nd May 2020 15:16
(Sharecast News) - Top White House health expert Anthony Fauci is confident that the US could begin to roll out a coronavirus vaccine by December.
Read moreFauci predicts US could have vaccine by end of 2020
22nd May 2020 15:16
(Sharecast News) - Top White House health expert Anthony Fauci is confident that the US could begin to roll out a coronavirus vaccine by December.
Read moreOxford University enrolling 10,260 more volunteers for late stage Covid-19 vaccine trials
22nd May 2020 12:43
(Sharecast News) - Oxford University and its partnership institutions have begun enrolling volunteers across Britain in the next phase of clinical trials for its vaccine against Covid-19.
Read moreAstraZeneca gets orphan drug designation for Enhertu
22nd May 2020 07:44
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo, has been granted orphan drug designation status for 'Enhertu' in the US, it announced on Friday, for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Read moreAstraZeneca gearing up to deliver Covid vaccine from September
21st May 2020 07:20
(Sharecast News) - AstraZeneca said on Thursday that it is collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine "widely accessible" in an equitable way, having concluded the first agreements for at least 400 million doses.
Read moreAstraZeneca's Lynparza gets FDA approval
20th May 2020 08:07
(Sharecast News) - Pharmaceutical giant AstraZeneca's drug Lynparza has been approved for the treatment of patients with a specific type of prostate cancer in the US.
Read moreAstraZeneca clears regulatory hurdles for Enhertu and Bevespi Aerosphere
18th May 2020 07:25
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo, announced on Monday that 'Enhertu', or trastuzumab deruxtecan, has been granted breakthrough therapy designation in the United States.
Read moreMonday broker round-up
11th May 2020 13:48
(Sharecast News) - Diploma: Peel Hunt downgrades to hold with a target price of 1,650p.
Read moreAstraZeneca upbeat on developments for Lynparza, Enhertu
11th May 2020 07:29
(Sharecast News) - AstraZeneca, alongside its partner MSD, announced on Monday that 'Lynparza', or olaparib, in combination with bevacizumab has been approved in the United States for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Read moreAstraZeneca gets another approval for 'Farxiga'
6th May 2020 08:06
(Sharecast News) - AstraZeneca said on Wednesday that 'Farxiga', or dapagliflozin, has been approved in the United States to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced ejection fraction, with and without type-2 diabetes.
Read moreCredit Suisse ups AstraZeneca price target on lung cancer drug
30th Apr 2020 14:52
(Sharecast News) - Credit Suisse raised its target price for AstraZeneca to reflect the potential of the FTSE 100 company's Tagrisso lung cancer treatment.
Read moreThursday broker round-up
30th Apr 2020 13:16
(Sharecast News) - Mitchells & Butlers: JP Morgan upgrades to overweight with a target price of 340p.
Read more